Axovant Sciences Ltd (NASDAQ:AXON) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 3,010,456 shares, a decrease of 31.3% from the November 15th total of 4,379,298 shares. Based on an average daily volume of 745,858 shares, the days-to-cover ratio is presently 4.0 days. Approximately 9.4% of the shares of the company are short sold.
Several equities analysts have recently commented on the company. Chardan Capital raised Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price for the company in a report on Wednesday. ValuEngine lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a report on Wednesday, September 27th. Jefferies Group reissued a “buy” rating and issued a $12.00 price objective on shares of Axovant Sciences in a report on Wednesday, September 27th. Finally, JMP Securities reissued an “outperform” rating and issued a $19.00 price objective (down from $36.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $14.14.
Several large investors have recently made changes to their positions in AXON. FMR LLC lifted its position in shares of Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after acquiring an additional 6,558,462 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Axovant Sciences during the 2nd quarter valued at $47,854,000. OxFORD Asset Management LLP lifted its position in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after acquiring an additional 777,505 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after acquiring an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Axovant Sciences during the 3rd quarter valued at $4,471,000. Institutional investors own 96.93% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.